Morgan Stanley Maintains Overweight on CME Group, Raises Price Target to $337
Morgan Stanley analyst Michael Cyprys maintains CME Group (NASDAQ:CME) with a Overweight and raises the price target from $330 to $337.
Share
Why It Matters
A big bank analyst thinks CME Group is a good choice right now. They raised their price target by $7 because they like the company's future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.